Goldman Sachs
SVA

Goldman Sachs’s Sinovac Biotech, Ltd SVA Stock Holding History

Goldman Sachs’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,668
Closed -$79K – 7178
2017
Q2 		$79K Buy
+11,668
New +$63.9K ﹤0.01% 6217
2016
Q1 		– Sell
-13,727
Closed -$79K – 7701
2015
Q4 		$79K Buy
13,727
+728
+6% +$3.92K ﹤0.01% 6307
2015
Q3 		$66K Sell
12,999
-22,203
-63% -$118K ﹤0.01% 6674
2015
Q2 		$185K Sell
35,202
-56,026
-61% -$296K ﹤0.01% 6204
2015
Q1 		$452K Sell
91,228
-38,895
-30% -$192K ﹤0.01% 5243
2014
Q4 		$681K Sell
130,123
-32,091
-20% -$164K ﹤0.01% 4973
2014
Q3 		$780K Sell
162,214
-4,589
-3% -$24.6K ﹤0.01% 4865
2014
Q2 		$941K Buy
166,803
+155,215
+1,339% +$943K ﹤0.01% 4748
2014
Q1 		$83K Buy
+11,588
New +$76.7K ﹤0.01% 6448

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's SVA Position: Q3 2017 in Review

Goldman Sachs sold out of Sinovac Biotech, Ltd (SVA) in Q3 2017, closing a stake of 11,668 shares — an estimated $79K sold.

Goldman Sachs first reported a position in SVA in Q1 2014 and held it in 9 quarters. The position peaked at $941K in Q2 2014. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2017.

  • Goldman Sachs reported no remaining Sinovac Biotech, Ltd position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 11,668 Sinovac Biotech, Ltd shares in Q3 2017, an estimated $79K.
  • Goldman Sachs first reported a position in Sinovac Biotech, Ltd in Q1 2014 and held it in 9 quarters.
  • Goldman Sachs's Sinovac Biotech, Ltd position peaked at $941K in Q2 2014.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.